Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 12, 2010, Pages 3185-3188

  Brasky, Theodore M ^a,b   Velicer, Christine M ^a,c   Kristal, Alan R ^a,b   Peters, Ulrike ^a,b   Potter, John D ^a,b   White, Emily ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NAPROXEN;

ADULT; AGED; ARTICLE; CANCER GRADING; COHORT ANALYSIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 78650342020     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0942     Document Type: Article

References (8)

1. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
2. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:S36-40.
3. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-5.
4. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004;10:7727-37.
5. Mahmud SM, Franco EL, Aprikian AG. Use of non-steroidal antiinflammatory drugs (NSAIDs) and prostate cancer risk: A meta-analysis. Int J Cancer 2010.
6. White E, Patterson RE, Kristal AR, Thornquist M, King I, Shattuck AL, et al. VITamins And Lifestyle cohort study: Study design and characteristics of supplement users. Am J Epidemiol 2004;159:83-93. (Pubitemid 38049425)
7. Woodward M. Formulae for Sample Size, Power and Minimum Detectable Relative Risk in Medical Studies. J R Stat Soc Ser D 1992;41:185-96.
8. Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and metaanalysis. Can Urol Assoc J 2009;3:323-30.